ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

0RAM Vistin Pharma Asa

11.25
0.00 (0.00%)
03 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Vistin Pharma Asa LSE:0RAM London Ordinary Share NO0010734122 VISTIN PHARMA ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 11.25 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 438.33M 45.6M 1.0282 10.94 498.88M

Vistin Pharma ASA: Second quarter and first half 2024 financial results

23/08/2024 6:40am

UK Regulatory


Vistin Pharma Asa (LSE:0RAM)
Historical Stock Chart


From Jun 2024 to Dec 2024

Click Here for more Vistin Pharma Asa Charts.
Vistin Pharma ASA: Second quarter and first half 2024 financial results

Oslo, Norway, 23rd of August 2024

Vistin Pharma ASA (VISTN) today announces the financial results for the second quarter of 2024.

Revenue in the second quarter ended at MNOK 106 compared to MNOK 107 in Q2 2023. Sales volume in the quarter was up by 4% compared to Q2 2023, currency neutral sales increased by 1%. Revenue for first half of 2024 ended at MNOK 210 compared to MNOK 208 YTD last year.

Second quarter EBITDA ended at MNOK 27 compared to MNOK 20 in Q2 2023, representing a 40% increase. EBITDA positively affected by product mix, favorable material cost prices and good cost control in quarter. EBITDA for first half of 2024 ended at MNOK 48 compared to MNOK 34 YTD 2023, an increase of 42%.

The net profit ended at MNOK 19.2 for the second quarter of 2024. Net profit positively affected with approx. MNOK 2.5 in the quarter due to fair value of future FX cash flow hedging contracts (unrealized gain - no cash effect in quarter).  

Cash dividend of NOK 0.50 per share distributed in June 2024. Additional dividend of NOK 0.50 per share planned to be distributed in Q4

The second quarter conference call, which will be held today 23rd of August at 8.30am (CET), will be available via webcast and audio through the following access points:

 

Webcast:
https://edge.media-server.com/mmc/p/v93s3oau

 

Telephone conference (online registration):
https://register.vevent.com/register/BIe6d25489e7ce45c18e8661e4d04d1d9a

 

The conference call will be held in English.    

Please find the Q2 report and presentation enclosed. The report will also be made available on www.vistin.com.

*****

For further information, please contact:

Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

 

Attachments

  • Vistin Pharma ASA Q2 report 2024
  • VistinPharma_Q2_24_presentation

1 Year Vistin Pharma Asa Chart

1 Year Vistin Pharma Asa Chart

1 Month Vistin Pharma Asa Chart

1 Month Vistin Pharma Asa Chart

Your Recent History

Delayed Upgrade Clock